ACAD · XBRL financial data

Acadia Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ACAD's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	212	231	—	—	—	—	—	—	—	—	—	—
Revenue from contracts with customers	212	231*	206	242	250	260*	244	265	279	284*	268	308
Cost of goods and services sold	15	18*	23	18	19	22*	20	21	22	26*	25	28
Gross profit	197	213	—	—	—	238*	—	—	—	258*	—	—
Research and development	157	67*	60	76	67	101*	78	78	88	85*	77	82
Selling, general and administrative	98	111*	108	117	133	130*	126	134	133	156*	171	160
Operating income (loss)	(58)	35*	15	30	32	154*	19	32	36	17*	(5)	38
Other income (expense)	2	0*	0	0	1	1*	1	1	1	1*	1	1
Income tax expense (benefit)	13	(6)*	4	4	6	17*	9	14	(27)	(247)*	0	15
Net income (loss)	(65)	46	17	33	33	144*	19	27	72	274*	4	32
Earnings per share, basic USD per share	(0.40)	0.28	0.10	0.20	0.20	0.86*	0.11	0.16	0.43	1.61*	0.02	0.18
Earnings per share, diluted USD per share	(0.40)	0.28	0.10	0.20	0.20	0.86*	0.11	0.16	0.42	1.58*	0.02	0.18
Weighted average shares, basic millions of shares	0	—	165	166	166	167*	167	168	169	170*	171	172
Weighted average shares, diluted millions of shares	0	—	167	166	166	166*	168	169	171	173*	173	173

Fiscal quarters (ACAD's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	98	189	205	177	155	320	218	254	258	178	282	385
Marketable securities	248	250	266	324	410	436	464	508	589	642	569	571
Accounts receivable	93	98	95	104	98	99	106	108	116	121	135	151
Inventory	25	40	67	86	87	92	103	111	106	111	112	109
Prepaid and other current assets	—	—	—	—	—	—	—	—	—	60	—	69
Total current assets	499	616	675	729	788	938	871	961	1,076	1,062	1,096	1,225
Property and equipment, net	5	5	4	4	4	4	3	4	4	8	15	17
Right-of-use asset	51	52	54	52	44	47	51	51	50	47	46	69
Total assets	633	749	855	914	977	1,188	1,132	1,226	1,331	1,564	1,605	1,743
Accounts payable	12	18	19	20	19	16	18	20	22	11	12	45
Accrued liabilities	197	237	311	318	325	379	284	310	335	266	293	317
Total current liabilities	210	254	331	338	344	395	303	330	357	277	306	361
Lease liability, non-current	48	48	49	47	40	42	45	45	43	41	39	60
Total liabilities	270	317	391	397	400	455	367	403	413	337	357	436
Accumulated deficit	(2,477)	(2,431)	(2,414)	(2,381)	(2,348)	(2,204)	(2,185)	(2,159)	(2,087)	(1,813)	(1,810)	(1,778)
Total stockholders' equity	362	432	464	517	577	733	765	822	917	1,227	1,248	1,307
Total liabilities and equity	633	749	855	914	977	1,188	1,132	1,226	1,331	1,564	1,605	1,743
Common shares outstanding (cover page) millions of shares	164	165	165	166	166	167	167	169	169	170	171	172

Fiscal quarters (ACAD's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(65)	46	17	33	33	144*	19	27	72	274*	4	32
Stock-based compensation	19*	18*	15	16*	26*	10*	11	14*	13*	13*	15	17*
Net cash from operating activities	(59)*	85*	29	25*	63*	40*	20	64*	74*	(49)*	34	101*
Purchases of property and equipment	—	0*	—	—	0*	0*	0	0*	0*	4*	5	5*
Net cash from investing activities	34*	(0)*	(14)	(56)*	(82)*	122*	(124)	(43)*	(79)*	(56)*	66	(9)*
Proceeds from issuing common stock	13*	5*	1	4*	0*	2*	2	16*	9*	23*	4	10*
Net cash from financing activities	13*	5*	1	4*	0*	2*	2	16*	9*	23*	4	10*
Net change in cash	(12)*	90*	16	(28)*	(19)*	164*	(102)	37*	4*	(82)*	105	103*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Acadia Pharmaceuticals	385	308	101*	172.3M	—	Q2 FY26 10-QJun 30, 2026
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Xenon Pharmaceuticals	120	not reported	(95)*	96.8M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Summit Therapeutics	419	not reported	(141)*	797.7M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Cytokinetics	255	29	(160)*	139.0M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026
Vericel	125	77	16*	51.2M	—	Q2 FY26 10-QJun 30, 2026
Recursion Pharmaceuticals	550	19	(77)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.